$0.76-2.6%Nov 11 close
Reported results on October 5, 2026; they are not in these figures yet.
Next earnings: December 15, 2026
Figures through June 30, 2026, from the 10-Q filed August 13, 2026
Company outlook: revenue of about $10.5M for Fiscal year 2026 — up 15.4% on a year earlier
Neuroone Medical Technologies Corp is scheduled to report next on December 15, 2026. The date comes from Nasdaq’s earnings calendar, and companies sometimes move it.
The quarter ending June 30, 2026, against the same quarter a year earlier.
| Measure | 3 months toJun 30, 2026 | 3 months toJun 30, 2025 | Change |
|---|---|---|---|
| Total Revenue | $2M | $1.7M | +16.34% |
| Profit | -$2M | -$1.5M | -33.68% |
| Profit per share | -$0.28 | -$0.19 | -47.37% |
| Free Cash Flow | -$1.1M | -$1.5M | +26.91% |
These are single quarters, not a trailing year — the figures elsewhere on this site cover twelve months and will be much larger. A seasonal business swings a long way between the two: ServiceNow earns $2.0B of free cash flow in its December quarter and $0.5B in its June one.
Compared against the same quarter a year earlier, not against an analyst forecast. A “beat” or “miss” needs a consensus estimate, which is licensed data we do not carry — and getting it wrong is worse than leaving it out.
Releases land before the open or after the close, so the window runs from the close before the report day to the close of the session after it — the reaction is inside it either way.
NeuroOne Medical Technologies Corporation is a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders. NeuroOne markets a minimally invasive and high-definition/high-precision electrode technology platform with four FDA-cleared product families: Evo® Cortical Electrodes, Evo® sEEG Electrodes, OneRF® Ablation System (for brain), and OneRF® Trigeminal Nerve Ablation System. These solutions offer the potential to reduce the number of hospitalizations and surgical procedures, lower costs, and improve patient outcomes by offering diagnostic and therapeutic functions. The Company is engaged in research and development for drug delivery, basivertebral nerve ablation and spinal cord stimulation programs.
The company’s own description, as it appears at the foot of the release.
The quote and the company description come from Neuroone Medical Technologies Corp’s Item 2.02 8-K filed October 5, 2026; the table is built from its quarterly reports. Read the release on EDGAR Share prices are split- and dividend-adjusted.
Neuroone Medical Technologies Corp’s own guidance, from its results release of October 5, 2026. It is the company’s statement of what it expects, not a forecast of ours.
As the company names it — a part of revenue, not the total.
Neuroone Medical Technologies Corp has no earnings call transcript available.